2Li S,Wang J H,Chen S L. Inhibitory effect of lingustrazine on proliferation of rabbit vascular smooth muscle cells after arterial injury[J].Acta Pharmacol Sin,1999,20(1):917.
3贾三庆.临床冠心病介入冶疗[M].北京:中国环境科学出版社,2002.394.
4Chen I Y，Circulation，1996年，93卷，1740页
5Wang Bingyin，J Am Coll Cardiol，1996年，28卷，1573页
6Brunner HR. Endothelin inhibition as a biooogic target for treating hyperteasion[J]. Am J Hypertens, 1998, 11 (4pt3):103S-109S.
7Torre-Amione G, Young JB, Durand J, et al. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class Ⅲ to Ⅳ congestive heart failure[J]. Circulation,2001,103 (7): 973 - 980.
8Moreau P, d'Uscio LV, Shaw S, et al. Angiotensin Ⅱ increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist[J]. Circulation, 1997,96:1593-1597.
9Walther T, Heringer-Walther S, Tschope R, et al. Opposite regulation of brain and C-type natriuretic peptides in the streptozotocin-diabetic cardiopathy[J]. J Mol Endocrinal, 2000, 24(3) :391 - 395.
10Kosuge M, Miyajima E, Kimura K, et al. Comparison of atrial natriuretic peptide versus nitroglycerin for reducing blood pressure in acute myocardial infarction[J]. Circulation, 1996,94:82-89.
